Erydel SpA
Latest round
- Series B
Last raised
- May 2015
Total raised
- $39M
Investors
- 3
About Erydel SpA
Founded in 2007, Erydel SpA specializes in biopharmaceutical solutions aimed at treating rare and complex conditions. The company has undergone strategic pivots, adapting to the evolving landscape of the biotechnology sector. Erydel operates primarily from its headquarters in Bresso, with operations that may extend to other locations. The company's CEO is Luca Benatti, who brings prior experience in biotechnology ventures.00 mn and concluded on July 21, 2023.Erydel's primary product is eDSP, a treatment for patients with Ataxia-Telangiectasia (A-T). This product utilizes the proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform, which encapsulates dexamethasone sodium phosphate within the patient's red blood cells. The goal of this approach is to improve drug delivery while reducing adverse effects.In the most recent fiscal year of 2021, Erydel reported no revenue.Erydel's strategy for future growth includes the ongoing development and commercialization of its eDSP product. The company aims to enter new markets, specifically expanding its reach in the United States and Europe post-regulatory approval. Additionally, a recent agreement in July 2023 for an all-stock acquisition by Quince Therapeutics, expected to close in Q3 2023, will enhance Erydel's resources and market position, allowing stockholders to receive USD 485 mn contingent on developmental milestones.
Who invested in Erydel SpA
3 investors across 3 rounds
See all investors in Erydel SpA
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Erydel SpA
Who invested in Erydel SpA?
Erydel SpA has 3 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Erydel SpA raised?
Erydel SpA has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Erydel SpA last raise money?
Erydel SpA's most recent round on record is a Series B, in May 2015.
What does Erydel SpA do?
Founded in 2007, Erydel SpA specializes in biopharmaceutical solutions aimed at treating rare and complex conditions.
Where is Erydel SpA headquartered?
Erydel SpA is headquartered in Italy.
Which VCs invest in companies like Erydel SpA?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Erydel SpA's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Erydel SpA? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.